{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:56:13Z","timestamp":1783691773938,"version":"3.55.0"},"reference-count":54,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Gliomas are notably challenging to treat due to their invasive nature and resistance to conventional therapies. The ABCG2 protein has attracted attention for its role in multidrug resistance, complicating treatment effectiveness. This study scrutinized the relationship between ABCG2 expression and glioma grade and the role of ABCG2 in the process of glioma progression, aiming to evaluate ABCG2 expression as a predictive factor of tumor progression and patient survival. Conducted at Dubrava University Hospital, Zagreb, Croatia, the study analyzed 152 glioma specimens from 2013 to 2022, assessing ABCG2 expression alongside standard clinical markers. A significant association was found between patients\u2019 survival and the ABCG2 profile (p = 0.003, r = 0.24), separately for patients who underwent chemotherapy (p = 0.0004, r = 0.32) and radiotherapy (p = 0.003, r = 0.29). Furthermore, the ABCG2 profile was significantly associated with disease progression (p = 0.007, r = 0.23), tumor grade (p = 0.0002, r = 0.31), and Ki67 expression (p = 0.0004, r = 0.31). ABCG2-positive tumor cells only showed association with Ki67 expression (p = 0.002, r = 0.28). The ABCG2 profile was found to affect the overall patient survival (p = 0.02) and represent a moderate indicator of tumor progression (p = 0.01), unlike the percentage of ABCG2-positive tumor cells. ABCG2 may serve as a marker of angiogenesis and vascular abnormalities within tumors, predicting glioma progression and treatment response. Targeting ABCG2 could enhance chemoradiotherapy efficacy and improve patient outcomes, which highlights its value in assessing tumor aggressiveness and designing treatment strategies.<\/jats:p>","DOI":"10.3390\/ijms25063116","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:52:11Z","timestamp":1709869931000},"page":"3116","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["ABCG2 Expression as a Potential Survival Predictor in Human Gliomas"],"prefix":"10.3390","volume":"25","author":[{"given":"Marina","family":"Ragu\u017e","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Dubrava University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, Catholic University of Croatia, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-1278","authenticated-orcid":false,"given":"Marko","family":"Tarle","sequence":"additional","affiliation":[{"name":"Department of Maxillofacial Surgery, Dubrava University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Dental Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danko","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cytology, Dubrava University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u010cedna","family":"Tomasovi\u0107-Lon\u010dari\u0107","sequence":"additional","affiliation":[{"name":"School of Medicine, Catholic University of Croatia, 10000 Zagreb, Croatia"},{"name":"Department of Pathology and Cytology, Dubrava University Hospital, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Chudy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Dubrava University Hospital, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonko","family":"Marinovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Dubrava University Hospital, 10000 Zagreb, Croatia"},{"name":"Medicine of Sports and Exercise Chair, Faculty of Kinesiology, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darko","family":"Chudy","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Dubrava University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A Summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00701-022-05301-y","article-title":"The WHO 2021 Classification of Central Nervous System tumors: A practical update on what neurosurgeons need to know minireview","volume":"164","author":"Torp","year":"2022","journal-title":"Acta Neurochir."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood-brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10555-007-9042-6","article-title":"ABCG2: Determining its relevance in clinical drug resistance","volume":"26","author":"Robey","year":"2007","journal-title":"Cancer Metastasis Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2008.11.003","article-title":"ABCG2: A perspective","volume":"61","author":"Robey","year":"2009","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1002\/humu.24418","article-title":"The human ATP-binding cassette (ABC) transporter superfamily","volume":"43","author":"Dean","year":"2022","journal-title":"Hum. Mutat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.113.088609","article-title":"Molecular pharmacology of ABCG2 and its role in chemoresistance","volume":"84","author":"Stacy","year":"2013","journal-title":"Mol. Pharmacol."},{"key":"ref_14","first-page":"1","article-title":"Human ABCG2: Structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/0008-5472.CAN-07-2545","article-title":"ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition","volume":"68","author":"Yin","year":"2008","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/00498254.2012.662726","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) localizes to the nucleus in glioblastoma multiforme cells","volume":"42","author":"Bhatia","year":"2012","journal-title":"Xenobiotica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11060-017-2422-z","article-title":"Expression and function of ABCG2 and XIAP in glioblastomas","volume":"133","author":"Emery","year":"2017","journal-title":"J. Neurooncol."},{"key":"ref_18","first-page":"1090","article-title":"Expression and significance of ABCG2 in human malignant glioma","volume":"26","author":"Chu","year":"2007","journal-title":"Ai Zheng Chin. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00432-009-0578-4","article-title":"ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma","volume":"135","author":"Jin","year":"2009","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11010-008-9722-8","article-title":"Chemoresistance in gliomas","volume":"312","author":"Lu","year":"2008","journal-title":"Mol. Cell Biochem."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Kang, H., Lee, H., Kim, D., Kim, B., Kang, J., Kim, H.Y., Youn, H., and Youn, B. (2022). An Overview of Current Therapeutic Strategies. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061308"},{"key":"ref_22","first-page":"4237","article-title":"The mouse Bcrp1\/Mxr\/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin","volume":"59","author":"Allen","year":"1999","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.lfs.2010.02.012","article-title":"ABCG2: A potential marker of stem cells and novel target in stem cell and cancer therapy","volume":"86","author":"Ding","year":"2010","journal-title":"Life Sci."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wu, Z.X., Yang, Y., Wang, J.Q., Narayanan, S., Lei, Z.N., Teng, Q.X., Zeng, L., and Chen, Z.S. (2021). Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.697927"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1523\/JNEUROSCI.5103-08.2009","article-title":"ABCG2 is upregulated in Alzheimer\u2019s brain with cerebral amyloid angiopathy and may act as a gatekeeper at the blood-brain barrier for Abeta(1-40) peptides","volume":"29","author":"Xiong","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/pharmrev.120.000025","article-title":"ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery","volume":"75","author":"Schulz","year":"2023","journal-title":"Pharmacol. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2019.00208","article-title":"Inhibitors of Human ABCG2: From Technical Background to Recent Updates With Clinical Implications","volume":"10","author":"Toyoda","year":"2019","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Begicevic, R.R., and Falasca, M. (2017). ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18112362"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.bcp.2012.01.002","article-title":"Role of breast cancer resistance protein (BCRP\/ABCG2) in cancer drug resistance","volume":"83","author":"Natarajan","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"Paterson","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: Expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","first-page":"935","article-title":"Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918","volume":"7","author":"Maliepaard","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2002.12.116","article-title":"Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918","volume":"20","author":"Kruijtzer","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1158\/0008-5472.CAN-03-2033","article-title":"Expression, up-regulation, and transport function of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier","volume":"64","author":"Cisternino","year":"2004","journal-title":"Cancer Res."},{"key":"ref_36","first-page":"867","article-title":"Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67","volume":"138","author":"Gerdes","year":"1991","journal-title":"Am. J. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1746-1596-7-32","article-title":"Hypoxia-inducible factor-2a is associated with ABCG2 expression, histology-grade and Ki67 expression in breast invasive ductal carcinoma","volume":"7","author":"Xiang","year":"2012","journal-title":"Diagn. Pathol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2015). Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med., 372, 2481\u20132498.","DOI":"10.1056\/NEJMoa1402121"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1038\/s41467-021-24206-5","article-title":"ATRX promotes heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress","volume":"12","author":"Teng","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_41","first-page":"203","article-title":"A distinct \u201cside population\u201d of cells in human tumor cells: Implications for tumor biology and therapy","volume":"4","author":"Foster","year":"2005","journal-title":"Cell Cycle"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drup.2016.05.001","article-title":"Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies","volume":"27","author":"Li","year":"2016","journal-title":"Drug Resist. Updates"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2174\/187152010794473957","article-title":"ABC transporters: Unvalidated therapeutic targets in cancer and the CNS","volume":"10","author":"Robey","year":"2010","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0925-4439(02)00095-9","article-title":"Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1","volume":"1587","author":"Hegedus","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"El Kheir, W., Marcos, B., Virgilio, N., Paquette, B., Faucheux, N., and Lauzon, M.A. (2022). Drug Delivery Systems in the Development of Novel Strategies for Glioblastoma Treatment. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061189"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"21365","DOI":"10.1039\/D3RA02969G","article-title":"Nanoparticle-based drug delivery systems targeting cancer cell surfaces","volume":"13","author":"Hong","year":"2023","journal-title":"RSC Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2174\/092986708783503258","article-title":"Strategies to overcome or circumvent P-glycoprotein mediated multidrug resistance","volume":"15","author":"Yuan","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12987-022-00359-3","article-title":"Extracellular vesicles through the blood-brain barrier: A review","volume":"19","author":"Polakovicova","year":"2022","journal-title":"Fluids Barriers CNS"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1602\/neurorx.2.1.86","article-title":"Blood-brain barrier active efflux transporters: ATP-binding cassette gene family","volume":"2","author":"Potschka","year":"2005","journal-title":"NeuroRx"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lyu, C., Wang, L., Stadlbauer, B., Buchner, A., and Pohla, H. (2022). A Pan-Cancer Landscape of ABCG2 across Human Cancers: Friend or Foe?. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415955"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-009-0600-6","article-title":"GFAP, Ki67 and IDH1: Perhaps the Golden Triad of Glioma Immunohistochemistry","volume":"118","author":"Paulus","year":"2009","journal-title":"Acta Neuropathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1750-3639.2003.tb00013.x","article-title":"Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: Evidence for distinct angiogenic subtypes","volume":"13","author":"Birner","year":"2003","journal-title":"Brain Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cncr.21973","article-title":"Histopathologic assessment of hot-spot microvessel density and vascular patterns in glioblastoma: Poor observer agreement limits clinical utility as prognostic factors: A translational research project of the European Organization for Research and Treatment of Cancer Brain Tumor Group","volume":"107","author":"Preusser","year":"2006","journal-title":"Cancer"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3116\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:41Z","timestamp":1760105441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":54,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063116"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063116","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}